Literature DB >> 34201767

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies.

Daniele Focosi1, Marco Tuccori2, Andreina Baj3, Fabrizio Maggi3.   

Abstract

We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1), and other strains (B.1.1.298 and B.1.258delta). While waiting from real world clinical efficacy, these data provide guidance for the treating physician.

Entities:  

Keywords:  COVID-19; LyCoV016; REGN10987; SARS-CoV-2; convalescent plasma; etesevimab; imdevimab; immune escape; mutations; neutralizing antibody

Mesh：

Substances：

Year:  2021        PMID： 34201767     DOI： 10.3390/v13071211

Source DB:  PubMed          Journal:  Viruses        ISSN： 1999-4915            Impact factor:   5.048


  26 in total

1.  Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: A case report.

Authors:  Noémie Zucman; Fabrice Uhel; Diane Descamps; Damien Roux; Jean-Damien Ricard
Journal:  Clin Infect Dis       Date:  2021-02-10       Impact factor: 9.079

2.  Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.

Authors:  Delphine Planas; Timothée Bruel; Ludivine Grzelak; Florence Guivel-Benhassine; Isabelle Staropoli; Françoise Porrot; Cyril Planchais; Julian Buchrieser; Maaran Michael Rajah; Elodie Bishop; Mélanie Albert; Flora Donati; Matthieu Prot; Sylvie Behillil; Vincent Enouf; Marianne Maquart; Mounira Smati-Lafarge; Emmanuelle Varon; Frédérique Schortgen; Layla Yahyaoui; Maria Gonzalez; Jérôme De Sèze; Hélène Péré; David Veyer; Aymeric Sève; Etienne Simon-Lorière; Samira Fafi-Kremer; Karl Stefic; Hugo Mouquet; Laurent Hocqueloux; Sylvie van der Werf; Thierry Prazuck; Olivier Schwartz
Journal:  Nat Med       Date:  2021-03-26       Impact factor: 53.440

3.  Neutralization Potential of Covishield Vaccinated Individuals Sera Against B.1.617.1.

Authors:  Pragya D Yadav; Gajanan N Sapkal; Priya Abraham; Gururaj Deshpande; Dimpal A Nyayanit; Deepak Y Patil; Nivedita Gupta; Rima R Sahay; Anita M Shete; Sanjay Kumar; Samiran Panda; Balram Bhargava
Journal:  Clin Infect Dis       Date:  2022-02-11       Impact factor: 9.079

4.  Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.

Authors:  Emma C Thomson; Laura E Rosen; James G Shepherd; Roberto Spreafico; Ana da Silva Filipe; Jason A Wojcechowskyj; Chris Davis; Luca Piccoli; David J Pascall; Josh Dillen; Spyros Lytras; Nadine Czudnochowski; Rajiv Shah; Marcel Meury; Natasha Jesudason; Anna De Marco; Kathy Li; Jessica Bassi; Aine O'Toole; Dora Pinto; Rachel M Colquhoun; Katja Culap; Ben Jackson; Fabrizia Zatta; Andrew Rambaut; Stefano Jaconi; Vattipally B Sreenu; Jay Nix; Ivy Zhang; Ruth F Jarrett; William G Glass; Martina Beltramello; Kyriaki Nomikou; Matteo Pizzuto; Lily Tong; Elisabetta Cameroni; Tristan I Croll; Natasha Johnson; Julia Di Iulio; Arthur Wickenhagen; Alessandro Ceschi; Aoife M Harbison; Daniel Mair; Paolo Ferrari; Katherine Smollett; Federica Sallusto; Stephen Carmichael; Christian Garzoni; Jenna Nichols; Massimo Galli; Joseph Hughes; Agostino Riva; Antonia Ho; Marco Schiuma; Malcolm G Semple; Peter J M Openshaw; Elisa Fadda; J Kenneth Baillie; John D Chodera; Suzannah J Rihn; Samantha J Lycett; Herbert W Virgin; Amalio Telenti; Davide Corti; David L Robertson; Gyorgy Snell
Journal:  Cell       Date:  2021-01-28       Impact factor: 66.850

5.  SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera.

Authors:  Alona Kuzmina; Yara Khalaila; Olga Voloshin; Ayelet Keren-Naus; Liora Boehm-Cohen; Yael Raviv; Yonat Shemer-Avni; Elli Rosenberg; Ran Taube
Journal:  Cell Host Microbe       Date:  2021-03-20       Impact factor: 21.023

6.  Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.

Authors:  Wilfredo F Garcia-Beltran; Evan C Lam; Kerri St Denis; Adam D Nitido; Zeidy H Garcia; Blake M Hauser; Jared Feldman; Maia N Pavlovic; David J Gregory; Mark C Poznansky; Alex Sigal; Aaron G Schmidt; A John Iafrate; Vivek Naranbhai; Alejandro B Balazs
Journal:  Cell       Date:  2021-03-12       Impact factor: 41.582

7.  Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study.

Authors:  Mark S Graham; Carole H Sudre; Anna May; Michela Antonelli; Benjamin Murray; Thomas Varsavsky; Kerstin Kläser; Liane S Canas; Erika Molteni; Marc Modat; David A Drew; Long H Nguyen; Lorenzo Polidori; Somesh Selvachandran; Christina Hu; Joan Capdevila; Alexander Hammers; Andrew T Chan; Jonathan Wolf; Tim D Spector; Claire J Steves; Sebastien Ourselin
Journal:  Lancet Public Health       Date:  2021-04-12

8.  Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization.

Authors:  Pengfei Wang; Ryan G Casner; Manoj S Nair; Maple Wang; Jian Yu; Gabriele Cerutti; Lihong Liu; Peter D Kwong; Yaoxing Huang; Lawrence Shapiro; David D Ho
Journal:  Cell Host Microbe       Date:  2021-04-18       Impact factor: 21.023

9.  Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016.

Authors:  Tyler N Starr; Allison J Greaney; Adam S Dingens; Jesse D Bloom
Journal:  Cell Rep Med       Date:  2021-04-05

Review 10.  Viral infection neutralization tests: A focus on severe acute respiratory syndrome-coronavirus-2 with implications for convalescent plasma therapy.

Authors:  Daniele Focosi; Fabrizio Maggi; Paola Mazzetti; Mauro Pistello
Journal:  Rev Med Virol       Date:  2020-09-21       Impact factor: 11.043
View more
  17 in total

1.  The Efficiency of Convalescent Plasma Therapy in the Management of Critically Ill Patients Infected With COVID-19: A Matched Cohort Study.

Authors:  Chun Pan; Hui Chen; Jianfeng Xie; Yingzi Huang; Yi Yang; Bin Du; Haibo Qiu
Journal:  Front Med (Lausanne)       Date:  2022-06-16

2.  Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity.

Authors:  Fuhua Wu; Shuang Luo; Yongshun Zhang; Yangsen Ou Hairui Wang Zhaofei Guo Chunting He Shuting Bai Penghui He Min Jiang Xiaoyan Chen Guangsheng Du Xun Sun
Journal:  Acta Pharm Sin B       Date:  2022-07-12       Impact factor: 14.903

3.  COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme.

Authors:  Clare L Fasching; Venice Servellita; Bridget McKay; Vaishnavi Nagesh; James P Broughton; Alicia Sotomayor-Gonzalez; Baolin Wang; Noah Brazer; Kevin Reyes; Jessica Streithorst; Rachel N Deraney; Emma Stanfield; Carley G Hendriks; Becky Fung; Steve Miller; Jesus Ching; Janice S Chen; Charles Y Chiu
Journal:  J Clin Microbiol       Date:  2022-06-29       Impact factor: 11.677

4.  Molecular detection of SARS-CoV-2 strains and differentiation of Delta variant strains.

Authors:  Vaughn Hamill; Lance Noll; Nanyan Lu; Wai Ning Tiffany Tsui; Elizabeth Poulsen Porter; Mark Gray; Tesfaalem Sebhatu; Kyle Goerl; Susan Brown; Rachel Palinski; Sasha Thomason; Kelli Almes; Jamie Retallick; Jianfa Bai
Journal:  Transbound Emerg Dis       Date:  2022-01-05       Impact factor: 4.521

5.  Comparative mutational analysis of SARS-CoV-2 isolates from Pakistan and structural-functional implications using computational modelling and simulation approaches.

Authors:  Abdullah Shah; Saira Rehmat; Iqra Aslam; Muhmmad Suleman; Farah Batool; Abdul Aziz; Farooq Rashid; Muhmmad Asif Nawaz; Syed Shujait Ali; Muhammad Junaid; Abbas Khan; Dong-Qing Wei
Journal:  Comput Biol Med       Date:  2021-12-25       Impact factor: 6.698

Review 6.  The biological and clinical significance of emerging SARS-CoV-2 variants.

Authors:  Kaiming Tao; Philip L Tzou; Janin Nouhin; Ravindra K Gupta; Tulio de Oliveira; Sergei L Kosakovsky Pond; Daniela Fera; Robert W Shafer
Journal:  Nat Rev Genet       Date:  2021-09-17       Impact factor: 53.242

7.  Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile.

Authors:  Jeffrey M Sturek; Tania A Thomas; James D Gorham; Chelsea A Sheppard; Allison H Raymond; Kristen Petros De Guex; William B Harrington; Andrew J Barros; Gregory R Madden; Yosra M Alkabab; David Y Lu; Qin Liu; Melinda D Poulter; Amy J Mathers; Archana Thakur; Dana L Schalk; Ewa M Kubicka; Lawrence G Lum; Scott K Heysell
Journal:  Microbiol Spectr       Date:  2022-02-23

Review 8.  Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.

Authors:  Maryam Noori; Seyed Aria Nejadghaderi; Shahnam Arshi; Kristin Carson-Chahhoud; Khalil Ansarin; Ali-Asghar Kolahi; Saeid Safiri
Journal:  Rev Med Virol       Date:  2021-07-19       Impact factor: 11.043

9.  Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants.

Authors:  Rafael Bayarri-Olmos; Ida Jarlhelt; Laust Bruun Johnsen; Cecilie Bo Hansen; Charlotte Helgstrand; Jais Rose Bjelke; Finn Matthiesen; Susanne Dam Nielsen; Kasper Karmark Iversen; Sisse Rye Ostrowski; Henning Bundgaard; Ruth Frikke-Schmidt; Peter Garred; Mikkel-Ole Skjoedt
Journal:  Front Immunol       Date:  2021-10-07       Impact factor: 7.561

10.  High seroprevalence for SARS-CoV-2 infection in South America, but still not enough for herd immunity!

Authors:  Susy Fanny Núñez-Zapata; Bruno Benites-Peralta; Percy Mayta-Tristan; Alfonso J Rodríguez-Morales
Journal:  Int J Infect Dis       Date:  2021-07-11       Impact factor: 3.623
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.